Preferred Label : Selumetinib Sulfate;
NCIt synonyms : Selumetinib Sulphate; 1h-Benzimidazole-6-Carboxamide,5-((4-Bromo-2-Chlorophenyl)Amino)-4-Fluoro-N-(2- Hydroxyethoxy)-1-Methyl-,
Sulphate (1:1); 5-((4-Bromo-2-Chlorophenyl)amino)-4-Fluoro-N-(2-Hydroxyethoxy)-1-Methyl-1H- Benzimidazole-6-Carboxamide
Sulphate; 5-((4-Bromo-2-Chlorophenyl)amino)-4-Fluoro-N-(2-Hydroxyethoxy)-1-Methyl-1H- Benzimidazole-6-Carboxamide
Sulfate; 1H-Benzimidazole-6-Carboxamide, 5-((4-Bromo-2-Chlorophenyl)Amino)-4-Fluoro-N-(2- Hydroxyethoxy)-1-Methyl-,
Sulfate (1:1);
NCIt definition : The sulfate salt of selumetinib, an orally active, small molecule with potential antineoplastic
activity. Selumetinib is an ATP-independent inhibitor of mitogen-activated protein
kinase kinase (MEK or MAPK/ERK kinase) 1 and 2. MEK 1 and 2 are dual specificity kinases
that are essential mediators in the activation of the RAS/RAF/MEK/ERK pathway, are
often upregulated in various cancer cells, and are drivers of diverse cellular responses,
including proliferation. Inhibition of both MEK1 and 2 by selumetinib prevents the
activation of MEK1/2 dependent effector proteins and transcription factors, thereby
leading to an inhibition of cellular proliferation in various cancers.;
UNII : 807ME4B7IJ;
InChIKey : GRKFGZYYYYISDX-UHFFFAOYSA-N;
CAS number : 943332-08-9;
Drug name : Koselugo;
Molecule name : AZD6244 Hydrogen Sulphate; AZD-6244 Hydrogen Sulfate;
Chemical formula : C17H15BrClFN4O3.H2O4S;
Origin ID : C95225;
UMLS CUI : C2987007;
Currated CISMeF NLP mapping
- Semantic type(s)
- UMLS correspondences (same concept)
- chemical_or_drug_affects_gene_product
- chemical_or_drug_has_mechanism_of_action
- chemical_or_drug_has_physiologic_effect
- concept_is_in_subset
- has_free_acid_or_base_form
- has_target
- is_component_of_chemotherapy_regimen
- is_salt_form_of
